Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2018 May 7;215(5):1349–1364. doi: 10.1084/jem.20171484

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2018 Chiang et al.

This article is distributed under the terms of an Attribution–Noncommercial–Share Alike–No Mirror Sites license for the first six months after the publication date (see http://www.rupress.org/terms/). After six months it is available under a Creative Commons License (Attribution–Noncommercial–Share Alike 4.0 International license, as described at https://creativecommons.org/licenses/by-nc-sa/4.0/).

PMC Copyright notice

Figure 5. — Hyperactive mTOR signaling was normalized by combination anti-Aβ treatment. (A and B) Representative Western blots and quantitation for hippocampal mTORC1-dependent phosphorylation of S6 ribosomal protein. (C and D) Western blots and quantitation for mTORC2-dependent phosphorylation of protein kinase B, also known as Akt. Note the y-axis scale in D, reflecting the dramatic elevation of mTORC2 activity in pretreatment APP/TTA mice compared with TTA controls. (E and F) Western blots and quantitation for cofilin phosphorylation downstream of mTORC2. Measurements are expressed as a ratio of phosphorylated to total protein for each marker. n = 8/group (6 for TTA). Dashed line in scatter plots indicates normalized mean expression in TTA control animals. Comparisons against pretreatment are shown; other post hoc comparisons are listed in Table S1. *, P < 0.05; **, P < 0.01; ***, P < 0.001. Error bars show means ± SEM.